Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 1 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,199 | -19.7% | 220 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $1,494 | +35.6% | 220 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,102 | +2.6% | 220 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,074 | -89.3% | 220 | -69.4% | 0.00% | -88.9% |
| Q3 2022 | $10,000 | -9.1% | 720 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $11,000 | +22.2% | 720 | 0.0% | 0.01% | +50.0% |
| Q1 2022 | $9,000 | -35.7% | 720 | -17.2% | 0.01% | -33.3% |
| Q4 2021 | $14,000 | -54.8% | 870 | -21.1% | 0.01% | -60.9% |
| Q3 2021 | $31,000 | -27.9% | 1,103 | -13.9% | 0.02% | -28.1% |
| Q2 2021 | $43,000 | +290.9% | 1,281 | +265.0% | 0.03% | +255.6% |
| Q1 2021 | $11,000 | -42.1% | 351 | -7.9% | 0.01% | -43.8% |
| Q4 2020 | $19,000 | -78.4% | 381 | -83.3% | 0.02% | -79.7% |
| Q3 2020 | $88,000 | +780.0% | 2,280 | +854.0% | 0.08% | +618.2% |
| Q2 2020 | $10,000 | – | 239 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |